Evidence map›Paper›PMID 30404809›Full record

ArticleJournal of virology2019

Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.

Xing Liu, Bin He

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Personalizing Oncolytic Immunovirotherapy Approaches.Molecular diagnosis & therapy · 2024
    Article
  3. Review
  4. Genetic Modifications That Expand Oncolytic Virus Potency.Frontiers in molecular biosciences · 2022
    Review
  5. Review
  6. Herpesvirus-mediated stabilization of ICP0 expression neutralizes restriction by TRIM23.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Xing LiuDepartment of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, Illinois, USA.
Bin HeDepartment of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, Illinois, USA tshuo@uic.edu.
Illinois College · USUniversity of Illinois Urbana-Champaign · US

Funding

Role of TBK1 in HSV persistencyR21AI112755 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HE, BIN · 2015 to 2016
$440k
NIAID NIH HHS R21 AI112755
6 · The paper itself

Abstract

Oncolytic herpes simplex virus 1 (HSV-1), devoid of the γ

Indexed as

Sequence DeletionA549 CellsAnimalsBreast NeoplasmsCell Line, TumorCell SurvivalChlorocebus aethiopsEukaryotic Initiation Factor-2FemaleHep G2 CellsHerpesvirus 1, HumanHT29 CellsHumansInterferon-alphaInterferon Regulatory Factor-3Oncolytic VirusesEukaryotic Initiation Factor-2gamma 34.5 protein, Human herpesvirus 1Interferon-alphaInterferon Regulatory Factor-3IRF3 protein, humanViral Proteinsherpes simplex virusoncolytic virusesviral replicationvirus-host interactions

Identifiers

PMID30404809
PMCPMC6321935
OpenAlexW2900142835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.